Unresectable HER2-Low Breast Carcinoma
1 clinical trials · Condition
◉ Watch Unresectable HER2-Low Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer (NCT07137416) | National Cancer Institute (NCI) | 2026-10-05 |
Track Unresectable HER2-Low Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.